Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Zixun Yan, Dehui Zou, Wenbin Qian, Ying Lu, Yuhua Li, Dongmei Ji, Xiaojian Zhu, Heng Mei, Ping Li, Changju Qu, Lei Zhang, Keshu Zhou, Hongmei Jing, Ting Niu, Chunyan Ji, Lanfang Li, Hua Yang, Fei Li, Wei Wang, Kailin Xu, Jinghua Zhao, Depei Wu, Yu Hu, Weili Zhao
Institutions: Shanghai Jiao Tong University, Ruijin Hospital, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Second Affiliated Hospital of Zhejiang University, Zhejiang University, Ningbo University, Zhujiang Hospital, Southern Medical University, Shanghai Medical College of Fudan University, Fudan University Shanghai Cancer Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan Union Hospital, Tongji University, First Affiliated Hospital of Soochow University, First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Henan Cancer Hospital, Peking University Third Hospital, Sichuan University, West China Hospital of Sichuan University, Shandong University, Qilu Hospital of Shandong University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, University of Hong Kong - Shenzhen Hospital, First Affiliated Hospital of Nanchang University, Qingdao University, Affiliated Hospital of Qingdao University, Affiliated Hospital of Xuzhou Medical College, Fosun Pharma (China)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405039085